Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020

This article is not included in any systematic review

This article is part of the following publication threads:
Loading references information
The study will evaluate the efficacy, safety, and immunogenicity of two vaccination schedules of an inactivated vaccine against SARS-CoV-2 infection in adults. Two doses of the vaccine will be administered in a 0,14 and a 0,28-day schedule. Follow-up of safety and efficacy will be assessed for 12 months after the first dose. Immunogenicity will be studied in a subgroup of participants.
Epistemonikos ID: faf05cd169d3ae6f3eacfe57bd219a0205a10f56
First added on: Dec 04, 2020